In the PDAC mouse models described above, Pbrm1 loss occurred simultaneously with the activation of oncogenic Kras and the deletion of Trp53, which prompted us to investigate whether Pbrm1 deletion in established PDAC has any precise effects on PDAC tumor cells. Here, KRAS is linked to neoplasm.